PET 방사성 트레이서 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The PET Radiotracer Market size is expected to reach USD 5.65 Billion in 2034 from USD 2.63 Billion (2025) growing at a CAGR of 8.84% during 2026-2034.

The global PET radiotracer market is expanding due to the increasing use of positron emission tomography in oncology, neurology, and cardiology diagnostics. Growing cancer incidence worldwide and rising demand for early disease detection are major drivers supporting market growth. PET radiotracers enable high-precision imaging, helping physicians diagnose and monitor complex medical conditions effectively.

Advancements in radiopharmaceutical development and growing research in molecular imaging are further strengthening market dynamics. Increased investments in nuclear medicine infrastructure and rising adoption of hybrid imaging systems such as PET/CT are contributing to demand expansion. Additionally, ongoing clinical research exploring new tracers for targeted imaging is broadening application scope.

Future prospects appear promising as personalized medicine and precision diagnostics gain importance. Development of novel tracers with improved specificity and shorter half-lives will enhance clinical efficiency. As healthcare systems continue investing in advanced diagnostic technologies, the PET radiotracer market is expected to witness sustained growth globally.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Radiotracer Type

• F-18 (FDG18)
• Ga-68 (FAPI)
• Others

By Application

• Cancer
• Heart Disease
• Gastrointestinal
• Endocrine
• Neurological Disorders
• Others

By End-user

• Hospitals
• Diagnostic Centers
• Others

COMPANIES PROFILED

• ABX advanced biochemical compounds GmbH Cambridge Isotope Laboratories Inc, Blue Earth Diagnostics, Cardinal Health, Eli Lilly and Company, GE Healthcare, IBA Radiopharma Solutions, Jubilant Pharma Limited, Lantheus Holdings Inc, Siemens Healthineers AG, Yantai Dongcheng Pharmaceutical Group Co Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PET RADIOTRACER MARKET: BY RADIOTRACER TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Radiotracer Type
• 4.2. F-18 (FDG18) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Ga-68 (FAPI) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PET RADIOTRACER MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Heart Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Gastrointestinal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Endocrine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Neurological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PET RADIOTRACER MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Diagnostic Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PET RADIOTRACER MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Radiotracer Type
  • 7.2.2 By Application
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Radiotracer Type
  • 7.3.2 By Application
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Radiotracer Type
  • 7.4.2 By Application
  • 7.4.3 By End-user
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Radiotracer Type
  • 7.5.2 By Application
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Radiotracer Type
  • 7.6.2 By Application
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL PET RADIOTRACER INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 ABX Advanced Biochemical Compounds GmbH (Cambridge Isotope Laboratories Inc.)
  • 9.2.2 Blue Earth Diagnostics
  • 9.2.3 Cardinal Health
  • 9.2.4 Eli Lilly And Company
  • 9.2.5 GE Healthcare
  • 9.2.6 IBA Radiopharma Solutions
  • 9.2.7 Jubilant Pharma Limited
  • 9.2.8 Lantheus Holdings Inc
  • 9.2.9 Siemens Healthineers AG
  • 9.2.10 Yantai Dongcheng Pharmaceutical Group Co. Ltd